{"id":"W2763742548","doi":"10.1093/annonc/mdx440.008","title":"MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Medicine; Internal medicine; Fulvestrant; Breast cancer; Metastatic breast cancer; Oncology; Hazard ratio; Letrozole; Anastrozole; Aromatase inhibitor; Tolerability; Cancer; Adverse effect; Estrogen receptor; Tamoxifen; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000324413,0.000469648,0.001229894,0.0004332109,0.0004105927,0.0007783051,0.0006160247,0.0005992948,0.01378974],"category_scores_gemma":[0.0005616056,0.0001815318,0.0008568816,0.0003621627,0.0002404731,0.0005303427,0.0003752613,0.001995227,0.00222111],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001038033,"about_ca_system_score_gemma":0.001219943,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001838141,"about_ca_topic_score_gemma":0.01108239,"domain_scores_codex":[0.9998884,0.00002536679,0.000007847954,0.00001308315,0.00001721326,0.00004803055],"domain_scores_gemma":[0.9998164,0.00002317425,0.00002719271,0.00001182639,0.00001493593,0.0001066393],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1298867,0.004345451,0.005511665,0.002527407,0.0008950162,0.001448082,0.0002221879,0.002317354,0.01965788,0.002177502,0.07352672,0.7574841],"study_design_scores_gemma":[0.2290385,0.1361839,0.138892,0.002974221,0.003432783,0.01363755,0.0005411162,0.008899319,0.02972195,0.007226368,0.4290659,0.0003863847],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.841091,0.06013789,0.001910453,0.0107042,0.002221952,0.001358321,0.006313547,0.001449371,0.07481327],"genre_scores_gemma":[0.9502562,0.01655096,0.002072726,0.004648916,0.0006650354,0.0003764161,0.004840915,0.0001434239,0.02044536],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01378974,"threshold_uncertainty_score":0.04613131,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07265391653121518,"score_gpt":0.4623746340739686,"score_spread":0.3897207175427534,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}